Results of clinical trials with an allogeneic melanoma tumor cell lysate vaccine: Melacine®

Vernon K. Sondak; Jeffrey A. Sosman

doi:10.1016/j.semcancer.2003.09.004

Results of clinical trials with an allogeneic melanoma tumor cell lysate vaccine: Melacine®

Vernon K. Sondak^*, Jeffrey A. Sosman

^*Corresponding author for this work

Medicine, Hematology Oncology Division

Research output: Contribution to journal › Review article › peer-review

100 Scopus citations

Abstract

The identification of proteins and carbohydrates associated with melanoma led to development of defined antigen vaccines. However, vaccines derived from whole allogeneic cells have a number of advantages. Melacine® is an allogeneic melanoma tumor cell lysate combined with an immunologic adjuvant, DETOX®. Phase I and II trials in stage IV melanoma showed low-level antitumor activity, but this vaccine has its greatest promise in the adjuvant setting. A phase III trial indicated a survival benefit for Melacine® in the subset of melanoma patients who express the HLA class I antigens A2 and/or HLA-C3. This finding must now be prospectively confirmed.

Original language	English (US)
Pages (from-to)	409-415
Number of pages	7
Journal	Seminars in Cancer Biology
Volume	13
Issue number	6
DOIs	https://doi.org/10.1016/j.semcancer.2003.09.004
State	Published - Dec 2003

Keywords

Adjuvant therapy
Cancer vaccines
HLA antigens
Immunotherapy
Melanoma

ASJC Scopus subject areas

Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.semcancer.2003.09.004

Cite this

@article{458ec974a4de4286a2eba79a536fabf5,

title = "Results of clinical trials with an allogeneic melanoma tumor cell lysate vaccine: Melacine{\textregistered}",

abstract = "The identification of proteins and carbohydrates associated with melanoma led to development of defined antigen vaccines. However, vaccines derived from whole allogeneic cells have a number of advantages. Melacine{\textregistered} is an allogeneic melanoma tumor cell lysate combined with an immunologic adjuvant, DETOX{\textregistered}. Phase I and II trials in stage IV melanoma showed low-level antitumor activity, but this vaccine has its greatest promise in the adjuvant setting. A phase III trial indicated a survival benefit for Melacine{\textregistered} in the subset of melanoma patients who express the HLA class I antigens A2 and/or HLA-C3. This finding must now be prospectively confirmed.",

keywords = "Adjuvant therapy, Cancer vaccines, HLA antigens, Immunotherapy, Melanoma",

author = "Sondak, {Vernon K.} and Sosman, {Jeffrey A.}",

year = "2003",

month = dec,

doi = "10.1016/j.semcancer.2003.09.004",

language = "English (US)",

volume = "13",

pages = "409--415",

journal = "Seminars in Cancer Biology",

issn = "1044-579X",

publisher = "Academic Press Inc.",

number = "6",

}

TY - JOUR

T1 - Results of clinical trials with an allogeneic melanoma tumor cell lysate vaccine

T2 - Melacine®

AU - Sondak, Vernon K.

AU - Sosman, Jeffrey A.

PY - 2003/12

Y1 - 2003/12

N2 - The identification of proteins and carbohydrates associated with melanoma led to development of defined antigen vaccines. However, vaccines derived from whole allogeneic cells have a number of advantages. Melacine® is an allogeneic melanoma tumor cell lysate combined with an immunologic adjuvant, DETOX®. Phase I and II trials in stage IV melanoma showed low-level antitumor activity, but this vaccine has its greatest promise in the adjuvant setting. A phase III trial indicated a survival benefit for Melacine® in the subset of melanoma patients who express the HLA class I antigens A2 and/or HLA-C3. This finding must now be prospectively confirmed.

AB - The identification of proteins and carbohydrates associated with melanoma led to development of defined antigen vaccines. However, vaccines derived from whole allogeneic cells have a number of advantages. Melacine® is an allogeneic melanoma tumor cell lysate combined with an immunologic adjuvant, DETOX®. Phase I and II trials in stage IV melanoma showed low-level antitumor activity, but this vaccine has its greatest promise in the adjuvant setting. A phase III trial indicated a survival benefit for Melacine® in the subset of melanoma patients who express the HLA class I antigens A2 and/or HLA-C3. This finding must now be prospectively confirmed.

KW - Adjuvant therapy

KW - Cancer vaccines

KW - HLA antigens

KW - Immunotherapy

KW - Melanoma

UR - http://www.scopus.com/inward/record.url?scp=0742321971&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0742321971&partnerID=8YFLogxK

U2 - 10.1016/j.semcancer.2003.09.004

DO - 10.1016/j.semcancer.2003.09.004

M3 - Review article

C2 - 15001159

AN - SCOPUS:0742321971

SN - 1044-579X

VL - 13

SP - 409

EP - 415

JO - Seminars in Cancer Biology

JF - Seminars in Cancer Biology

IS - 6

ER -

Results of clinical trials with an allogeneic melanoma tumor cell lysate vaccine: Melacine®

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this